Saturday 17 October 2026
Export HOWL’s income statement to Excel — free account
Werewolf Therapeutics, Inc.
HOWL Healthcare Biotechnology
Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023. In the quarter to June 2026, revenue grew 256.1%, EPS grew 120.0% and free cash flow grew 146.5%, each against the same quarter a year earlier.
0.98
0.02
−2.00%
Follow HOWL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | 0.00 |
P/S ratio |
— | — | — | 0.72 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | 2.64 | |
P/B ratio |
— | — | — | 1.07 | |
Price to Tangible BV |
— | — | — | 1.07 | |
EV/Sales |
— | — | — | 0.70 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (0.57) | |
EV/FCF |
— | — | — | (0.57) | |
Quick Ratio |
3.73 | 1.58 | 1.21 | 2.80 | |
Current Ratio |
3.87 | 1.62 | 1.27 | 2.91 | |
Net Debt/EBITDA |
2.87 | 6.33 | 3.61 | (2.29) | |
Debt/Assets |
27.20% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.73 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.42 | |
Operating CF/Net income |
0.93 | 1.32 | 0.78 | 1.81 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.17 | |
Interest Coverage |
(11.73) | (6.88) | (9.70) | 15.07 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 29.34% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 36.57% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 2.00% | |
Graham Net Nets |
— | — | — | 0.86 | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (202.78%) | |
Free Cash Flow Yield |
— | — | — | (170.76%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.43 | |
Operating CF per Share |
(0.33) | (0.24) | (0.22) | 0.14 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.01 | |
Free Cash Flow per Share |
(0.33) | (0.24) | (0.22) | 0.15 | |
Cash per Share |
1.43 | 1.24 | 0.96 | 0.45 | |
Shareholders Equity per Share |
0.65 | 0.54 | 0.25 | 0.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.65 | 0.54 | 0.25 | 0.34 | |
Free Cash Flow |
(15.16) | (11.02) | (10.60) | 7.05 | |
Working Capital |
50.57 | 22.44 | 10.22 | 15.03 | |
Capital Expenditures |
— | — | — | 0.42 | |
Net Current Asset Value |
18.16 | 14.00 | 2.91 | 15.03 | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
— | — | — | (0.02) | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
1.16 | 1.89 | 2.28 | 2.36 | |
Average Assets |
109.83 | 98.16 | 82.63 | 58.36 | |
Average Common Equity |
59.50 | 49.10 | 34.75 | 28.88 |
Columns are period end dates